NEW YORK – Triumvira Immunologics, based in the US and Canada, on Monday announced it has dosed the first cancer patient with its HER2-targeted autologous T-cell therapy, dubbed TAC01-HER2, in the TACTIC-2 trial.
In the Phase I/II trial, researchers will evaluate the safety, tolerability, and efficacy of TAC01-HER2 in approximately 70 patients with HER2-positive metastatic, advanced, unresectable solid tumors, including breast, gastric, and other cancers. The first patient dosed in the study is being treated at MD Anderson Cancer Center. Researchers at the Dana-Farber Cancer Institute in Boston and the University of Chicago are also enrolling participants.
Triumvira develops autologous and allogeneic T-cell therapies for solid tumors and blood cancers using its T-cell Antigen Coupler (TAC) technology. The company claims that its platform activates the natural function of T cells to identify and kill cancer cells differently from existing CAR T-cell therapies and engineered T-cell treatments.
"The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology," Triumvira CEO Paul Lammers said in a statement. "We look forward to sharing our progress with this program as we build out a pipeline of candidates targeting solid tumors."
Triumvira is headquartered in Austin, Texas, and has research facilities in Hamilton, Ontario.